• Careers
  • Contact
Kura 02
  • About Us
    • Our Commitment
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
    • Clinical Advisors
    • The Story Behind Our Name
  • Our Focus
    • Precision Medicines
    • Targeted Therapeutics
    • Biomarkers
  • Patients & Caregivers
    • Our Message to Patients
    • Participating in Clinical Trials
    • HRAS Mutant Squamous Head and Neck Cancer
    • Acute Myeloid Leukemia (AML)
  • Clinical Trials
    • AIM-HN – HNSCC
    • KOMET-001 – AML
    • KURRENT – HNSCC
  • Our Pipeline
    • Tipifarnib
    • KO-539
    • Scientific Publications
    • Access to Investigational Drugs Outside a Clinical Trial
  • Investors and Media
    • Overview
    • Press Releases
    • Events & Presentations
      • Calendar Events
      • Corporate Presentations
      • Scientific Publications
    • Corporate Governance
      • Committees and Governance Documents
      • Board of Directors
      • Leadership Team
    • SEC Filings
    • Annual Report and Proxy
    • Stock Quote
    • Analyst Coverage
    • FAQs
    • Contact Us
  • Overview
  • Press Releases
  • Events & Presentations
    • Calendar Events
    • Corporate Presentations
    • Scientific Publications
  • Corporate Governance
  • SEC Filings
  • Annual Report and Proxy
  • Stock Quote
  • Analyst Coverage
  • FAQs
  • Contact Us

Tools

Print

RSS Feeds

Email Alerts

Corporate Presentations

Date Title
Aug 3, 2022
  • Add Files
    Kura Oncology - Corporate Presentation - August 2022 5 MB
Dec 5, 2020
  • Add Files
    Investor Event Presentation 1.7 MB
© 2022 Kura Oncology, Inc. All Rights Reserved Terms of Use Privacy Policy
Scroll to top